Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
; : 408-412, 2019.
Article
in En
| WPRIM
| ID: wpr-719415
Responsible library:
WPRO
ABSTRACT
Epidermal growth factor receptor (EGFR)‒tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations. However, the vast majority of patients acquire resistance following successful treatment. A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib. CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%). Another 53-year-old female patient developed systemic progression after 10 months of osimertinib. CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation. The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.
Key words
Full text:
1
Index:
WPRIM
Main subject:
Phosphotransferases
/
Population Characteristics
/
Biopsy
/
Exons
/
Carcinoma, Non-Small-Cell Lung
/
ErbB Receptors
/
Gene Frequency
/
Liver
/
Lung
Type of study:
Prognostic_studies
Limits:
Female
/
Humans
Language:
En
Journal:
Cancer Research and Treatment
Year:
2019
Type:
Article